Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Subscribe To Our Newsletter & Stay Updated
